This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
The Beat AML Master Trial was designed to explore the feasibility of genomically driven precision medicine in patients with newly diagnosed acute myeloid leukemia. Preliminary results suggest that necessary testing can be completed within a week, and that patients matched to therapies may live longer—although survival data should be interpreted with caution.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2021
Volume 11, Issue 1
Volume 11, Issue 1
Precision Medicine Feasible in AML
Jump to section
Advertisement